Xofluza 30 mg, Granulat zur Herstellung einer Suspension zum Einnehmen (Beutel)

7680680680032 CH-68068 J05AX25 08.03.0.

No images available

Details

Product number
6806803
CPT
-
Packaging group
1
Unit
Beutel
Composition
baloxavirum marboxilum 30 mg, mannitolum, maltitolum 525 mg, natrii chloridum corresp. natrium 17.7 mg, hypromellosum, povidonum K 25, silica colloidalis anhydrica, sucralosum, talcum, aromatica (Erdbeer) ad granulatum, pro charta.

Articles (1)

Xofluza 30 mg, Granulat zur Herstellung einer Suspension zum Einnehmen (Beutel)
Granulat
1
View

Official Swissmedic V2 data

Additional information from the official database

Detailed composition

Substance Quantity Type Category
baloxavirum marboxilum
30.0 MG Substance Wirkstoff (Principe actif)
mannitolum
- Substance HNIDK
maltitolum
525.0 MG Substance HBESI
natrii chloridum
- Substance HNIDK
natrium
17.7 MG Substance HBESI
hypromellosum
- Substance HNIDK
povidonum K 25
- Substance HNIDK
silica colloidalis anhydrica
- Substance HNIDK
sucralosum
- Substance HNIDK
talcum
- Substance HNIDK
aromatica
- Substance AROMA

Authorization holder

Roche Pharma (Schweiz) AG

4058 Basel

Authorization information

Swissmedic authorization number
68068
Drug name
Xofluza, Granulat zur Herstellung einer Suspension zum Einnehmen
Galenic form
GRAS
ATC Code
J05AX25
Authorization status
Z
Dispensation category
B
First authorization
19/11/2021
Authorization expiration date
31/12/9999
IT number
08.03.0.
Domain
Human medicine
Field of application
Behandlung von Influenza, Influenza-Postexpositionsprophylaxe

Packaging details

Description (FR)
XOFLUZA susp 30 mg 1 pce
Description (DE)
XOFLUZA Susp 30 mg 1 Stk
Market launch
05/08/2026
Market withdrawal
05/08/2026
Narcotic (BTM)
No

Other packaging sizes

XOFLUZA gran 2 mg/ml pour susp fl 20 ml
1 FLAS
View
XOFLUZA susp 10 mg 2 pce
2 BEU
View
XOFLUZA susp 40 mg 1 pce
1 BEU
View
Buy us a coffee Explore the data